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Objective. CD8 T cells lacking CD28 were orig-
inally reported to be a characteristic feature of juvenile
idiopathic arthritis (JIA), but the relevance of these
unusual cells to this disease remains to be elucidated.
Because of recent evidence that loss of CD28 cells is
typical of terminally differentiated lymphocytes, the aim
of this study was to examine functional subsets of CD8
T cells in patients with JIA.
Methods. Blood and/or waste synovial fluid sam-
ples were collected from children with a definite diag-
nosis of JIA (n  98). Deidentified peripheral blood
(n  33) and cord blood (n  13) samples from healthy
donors were also collected. CD8 and CD4 T cells
were screened for novel receptors, and where indicated,
bioassays were performed to determine the functional
relevance of the identified receptor.
Results. JIA patients had a naive T cell compart-
ment with shortened telomeres, and their entire T cell
pool had reduced proliferative capacity. They had an
overabundance of CD31CD28nullCD8 T cells, which
was a significant feature of oligoarticular JIA (n  62)
as compared to polyarticular JIA (n  36). CD31
CD28nullCD8 T cells had limited mitotic capacity and
expressed high levels of the senescence antigens histone
H2AX and/or p16. Ligation of CD31, which was inde-
pendent of the T cell receptor (TCR), sufficiently in-
duced tyrosine phosphorylation, vesicle exocytosis, and
production of interferon- and interleukin-10.
Conclusion. These data provide the first evidence
of cell senescence, as represented by CD31CD28null
CD8 T cells, in the pathophysiology of JIA. Activation
of these unusual cells in a TCR-independent manner
suggests that they are maladaptive and could be poten-
tial targets for immunotherapy.
Juvenile idiopathic arthritis (JIA) is the most
prevalent rheumatic disease of childhood, occurring
before the age of 16 years (1). Oligoclonal T cells
comprise a large proportion of joint infiltrates; some
clones go into the circulation and persist for years (2).
Clonotypes reactive to endogenous proteins or to patho-
gens have been reported, but clones that are diagnostic/
prognostic of JIA or those common to all patients are
unknown. Neither the driving force of T cell oligoclo-
nality nor the identity of pathogenic clonotypes is
known. Nevertheless, T cells play an important role in
the pathophysiology of JIA because they are important
sources of inflammatory cytokines such as tumor necro-
sis factor  (TNF) and interleukin-6 (IL-6) that are the
targets of biologic therapies (3). Some CD4 T cells
also have suppressive activity, the dysregulation of which
is thought to contribute to the disease process of JIA (4).
Hence, there is impetus to examine subsets of T cells and
how they relate to JIA disease (1). Identification of
culprit T cells could pave the way to cell-targeted
therapies as an alternative to current broad-spectrum
anticytokine biologic agents and synthetic pharmaceuti-
cals.
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In the late 1990s, Wedderburn et al (5) reported
that children with JIA have an overrepresentation of
CD8 T cells lacking CD28, the major costimulatory
receptor required to sustain conventional T cell receptor
(TCR)–driven activation. This observation has become
increasingly significant, as more-recent studies demon-
strated that CD28nullCD8 T cells are biologic indica-
tors of normal chronologic aging of the immune system
(6). Furthermore, young adults with chronic inflamma-
tory diseases, such as rheumatoid arthritis (RA), also
carry disproportionately large numbers of similar
CD28nullCD4 T cells for their age, and the size of this
CD4 subset has been correlated with the severity of RA
(7).
Such differential representation of CD28null T
cells in the CD8 and CD4 compartments in JIA and
adult RA, respectively, is consistent with clinical and
genetic evidence that these two diseases are separate
entities, albeit with some documented similarity in the
joint pathology (8). JIA does not become RA when the
affected child enters adulthood. An exception, however,
are patients diagnosed in adolescence (mostly girls)
with rheumatoid factor (RF)–positive polyarthritis,
which could be an early presentation of RA (9). There-
fore, investigating the biology of CD28nullCD8 T cells
in patients with JIA will improve our understanding of
the immunologic pathways unique to this childhood
disease.
In healthy adults, CD28nullCD8 T cells have
shortened telomeres as compared to those on CD28
cells (10), indicating a long replicative history consistent
with somatic cells that are already in an advanced
stage(s) of senescence. Such cells are nevertheless func-
tionally active, and some of their effector functions have
been attributed to other costimulatory receptors that
replace the defunct CD28 (11). Since human CD28null T
cells have a memory phenotype and classic memory T
cell responses are less dependent on CD28 costimula-
tion (12), we evaluated a provocative hypothesis that
CD28nullCD8 T cells in children with JIA represent a
prematurely senescent subset with maladaptive function
mediated by novel receptors in a TCR-independent
manner. Plausibility of this suggestion could be deduced
from animal models of lymphopenic states demonstrat-
ing low levels of TCR-independent cytokine-driven cel-
lular activation in peripheral T cell homeostasis (13). We
therefore screened for receptors other than traditional
costimulators that are expressed on CD28nullCD8 T
cells in JIA.
PATIENTS AND METHODS
Study subjects. Research on human subjects was con-
ducted in accordance with the Declaration of Helsinki, using
protocols approved by Institutional Review Boards of the
University of Pittsburgh and the Mayo Clinic. Children with
JIA, with the consent of their legal guardians, were recruited
from the rheumatology clinics of the University of Pittsburgh
Medical Center (UPMC) Children’s Hospital of Pittsburgh,
and Mayo Clinic. Diagnosis and determination of oligoarticu-
lar and polyarticular JIA were based on the International
League of Associations for Rheumatology revised clinical
criteria for JIA (14). Following signed informed consent/
assent, blood samples were obtained by routine venipuncture,
and the patients’ clinical data at the time of consent were
abstracted from the medical record. In patients who underwent
arthrocentesis as part of routine care prescribed by their
rheumatologists, the waste synovial fluid (SF) was collected. In
8 patients, paired samples of SF and blood were obtained on
the same day. Waste, deidentified peripheral blood samples
from healthy children, and deidentified cord blood samples
from uncomplicated births were also obtained from Labora-
tory Services of UPMC Children’s Hospital, and UPMC
Magee Women’s Hospital Research Institute, respectively.
The clinical characteristics of the study subjects are
summarized in Table 1. The JIA patients were of various ages
at disease onset, had various disease durations, and were
taking multiple medications. The age and sex distribution were
comparable between the healthy subjects and the JIA patients.
While not all of the patients had serologic data on record, half
of the patients who had been tested were antinuclear antibody
positive, and 2 of the patients with polyarticular JIA were RF
positive. Some of the patients had uveitis, as indicated by the
use of topical ocular steroids.
Flow cytometry. The phenotypes of T cells in peri-
pheral blood mononuclear cells (PBMCs), SF, and cell cultures
were determined by multicolor flow cytometry protocols estab-
lished previously (6,15). Fluorochrome-conjugated antibodies
(from BD, eBioscience, and BioLegend) to the classic T cell
markers TCR, CD3, CD4, CD8, and CD28, the activation
antigens CD25 and CD69, and the adhesion molecule CD31
were used to identify T cell populations. To identify senescent
cells, permeabilized cell preparations were stained with anti-
bodies to p16 and/or histone H2AX, 2 classic markers of
senescence in somatic cells (16,17).
Telomeres were measured using the flow cytometry
and fluorescence in situ hybridization technique (18). Analysis
focused on CD45RACD4 T cells, since CD45RA, as a
naive cell marker, is reliable for CD4 T cells, but not for
CD8 T cells (19). Quantum TM24 beads (Bangs Laborato-
ries) with a quantitative range of fluorochrome molecules were
used for cytometer calibration and to establish a standard
curve for the assay according to the manufacturer’s specifica-
tions. Telomere length was expressed as the mean equivalent
soluble fluorescence (MESF), which was calculated from the
following linear regression equation: MESF  (fluorescence
units of the sample – fluorescence units of the blank)/slope.
All cytometry experiments included antibody isotype
controls, cells stained individually with each indicated marker,
and multicolor beads (Bangs Laboratories) for signal calibra-
tion and for offline calculation of compensation matrices.
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Cytometry was performed on an LSRII cytometer (BD), and
analysis of cell populations was done offline using FlowJo
software (Tree Star). Cell populations were determined using
previously described electronic gating strategies (6,15).
Cell activation assays. T cell activation assays were
performed using primary CD31CD8 T cells purified from
PBMC or SF samples (negative selection with Rosette Sep;
StemCell Technologies). Jurkat and JRT3 cells (ATCC) were
used as internal system controls. Activation bioassays with 2
g/ml of anti-TCR/ (1P26; BioLegend) or 5 g/ml of
anti-CD3 (OKT3; Centocor Ortho Biotech) followed estab-
lished procedures (15,20). For stimulations using anti-CD31
(WM59; eBioscience) and recombinant CD38-Ig (R&D Sys-
tems), optimal concentrations of 1 g/ml and 10 g/ml,
respectively, were empirically determined. Stimulating agents
were either cross-linked in solution with species-specific anti-Ig
or immobilized in tissue culture plates according to published
procedures (15,20). All activation assays included Ig isotype
and medium-only controls.
At the indicated time periods, cells were harvested and
immunostained for CD25, CD69, phospho-tyrosine (4G10;
Millipore), and granzyme/CD107a (BD). The latter 2 mole-
cules were determined from permeabilized cells using Cy-
toperm reagent (BD). For granzyme detection, GolgiPlug/Stop
reagent (BD) was added to cultures during the last 6 hours of
incubation. Markers of cell activation were measured by
multicolor flow cytometry as described above. The culture
supernatants were also harvested, and the cytokine content was
measured by the Luminex system (6,15).
Proliferation assays on primary T cells in PBMC or SF
samples were performed using standard bioassays using 5,6-
carboxyfluorescein diacetate succinimidyl ester (CFSE-DA)
(6). Subsets of dividing or nondividing cells were identified by
immunostaining for CD4, CD8, CD28, CD31, and histone
H2AX after 5 days in culture.
For the analysis of in vitro senescence cultures, puri-
fied CD28 T cells from PBMCs were subjected to repeated
stimulations with irradiated allogeneic PBMCs and Epstein-
Barr virus–transformed lymphoblastoid cells, anti-CD3
(OKT3), and recombinant IL-2 (Proleukin; Chiron), as de-
scribed previously (21). Cell phenotypes of the cultures were
determined by flow cytometry 7 days after each stimulation
cycle.
For analysis of T cell population doubling, cultures of
T cells derived from PBMC or SF samples were monitored
according to the procedure described by Koetz et al (22).
Statistical analysis. Data were analyzed nonpara-
metrically using PASW Statistics version 18 software (SPSS).
Data for each sample group were displayed as box-and-whisker
median plots. Kruskal-Wallis analysis of variance (ANOVA)
was used to determine differences between 3 or more groups,
with post hoc comparison between any 2 groups examined by
least squares difference or by Tukey’s statistic. Curve-fitting
ANOVA was carried out for repeated measures over a given
time period, as appropriate. P values less than 0.05 were
considered significant.
RESULTS
Intrinsic activated state and replicative pressure
of T cells in JIA. The physiologic milieu in autoimmune
disorders is considered an environment of persistent
immune activation. Cytometric survey of cell phenotypes
in blood samples from patients with JIA showed larger
proportions of CD4 and CD8 T cells coexpressing
the classic activation antigens CD25 and CD69 (range
5–15%) as compared to healthy controls (Figure 1A).
JIA patients also had higher expression of CD25/CD69
(up to 35%) on SF T cells. Associated with this activated
state, naive CD45RACD4 T cells from JIA patients
had significantly shorter telomeres than did those from
either healthy children or cord blood controls (Figure
1B). The proliferative population-doubling capacity of
the entire blood T cell compartment was also signifi-
Table 1. Characteristics of the study cohort*
Healthy
subjects,
PBMCs
Oligoarticular
JIA patients
Polyarticular
JIA patients
PBMCs SF PBMCs SF
No. of samples 33 20 51 21 17
No. male/female 13/20 7/13 16/35 7/14 5/12
Mean age, years
Boys
At consent for study 6.1 9.4 10.4 9.4 10.4
At disease onset – 9.4 10.9 12.5 9.3
Girls
At consent for study 8.1 9.7 12.5 9.7 12.1
At disease onset – 8.4 10.0 10.9 11.7
Mean disease duration, years – 4.4 5.1 7.7 6.3
No. of medications taken†
NSAIDs – 20 45 21 17
Steroids, oral – 2 3 10 6
Steroids, IA – 17 43 13 15
Steroids, ocular (topical) – 1 7 2 1
Steroids, IV – 0 2 1 0
Methotrexate – 8 19 21 12
Biologic agents – 9 12 15 12
Other medications – 0 5 1 7
Autoantibodies, no. positive/
no. tested
ANA – 7/16 19/33 7/12 5/7
RF – 0/5 0/23 1/14 1/7
HLA–B27 – 1/8 4/10 0/0 2/5
* Peripheral blood mononuclear cell (PBMC) and synovial fluid (SF)
samples were obtained at different time points, except for 8 paired
samples of PBMCs and SF from 6 patients with oligoarticular juvenile
idiopathic arthritis (JIA) and 2 with polyarticular JIA (see Results).
Clinical data from the latter 8 patients were entered only once. IA 
intraarticular; IV  intravenous; ANA  antinuclear antibody; RF 
rheumatoid factor.
† Total numbers of medications were determined by simple tally at the
time of consent for study. Some patients were taking multiple medi-
cations. Nonsteroidal antiinflammatory drugs (NSAIDs) consisted of
ibuprofen, naproxen, meloxicam, tolmetin, indomethacin, and diclofe-
nac. Biologic agents consisted of etanercept, infliximab, and adali-
mumab. Other medications consisted of hydroxychloroquine and
sulfasalazine.
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cantly reduced among the patients (Figure 1C). Addi-
tionally, SF T cells had overall lower proliferative capac-
ity than blood T cells, a property consistent with their
more rapid turnover (23). All of these data indicate that
T cells are under replicative pressure in JIA.
CD28 deficiency and CD31 expression on CD8
T cells with limited mitotic capacity in JIA. The pheno-
types of nondividing T cells were further explored under
conditions of potent stimulation with allogeneic cells
and anti-CD3. By standard CFSE-DA assay, 30% of
JIA blood T cells remained CFSE-DAhigh, indicating
limited or no capacity for cell division (Figure 2A). In
contrast, the vast majority (98%) of blood T cells from
healthy controls underwent mitosis, with a negligible
number of CFSE-DAhigh cells (Figure 2B). The mitoti-
cally restricted population was predominantly CD8 T
cells that lacked CD28, but expressed CD31, a molecule
known to facilitate tissue invasion by normal granulo-
cytes (24). Virtually all CD31CD28nullCD8 T cells
expressed high levels of CD69, indicating full cellular
activation, rather than quiescence, in response to stim-
ulation (Figure 2A). These unusual CD8 T cells also
Figure 2. CD8 T cells with restricted mitotic capacity obtained from
patients with juvenile idiopathic arthritis (JIA) lack CD28, but express
CD31 and histone H2AX. A and B, Peripheral blood mononuclear
cells (PBMCs) from JIA patients (A) and healthy controls (HC) (B)
were analyzed by 5,6-carboxyfluorescein diacetate succinimidyl ester
(CFSE-DA) assay. Results are representative of 7 experiments. CD3
T cells that remained CFSE-DAhigh (yellow area in A), were further
examined, and it was shown that90% were CD8 T cells that lacked
CD28 but expressed various levels of CD31, CD69, and histone
H2AX, depending on the donor. Histone H2AX expression in
CD4 T cells was negligible. Numbers in each compartment are the
percentage of positive cells. C, As an internal system control, pheno-
types of purified CD28 T cells from healthy controls were monitored
through several rounds of stimulation (stim 1–3) using an in vitro
senescence system (23). Results show the CD28, CD31, and histone
H2AX expression profiles after the third stimulation cycle and are
representative of 10 experiments.
Figure 1. T cells from patients with juvenile idiopathic arthritis (JIA)
have an activated phenotype and are under replicative pressure. A,
Peripheral blood mononuclear cell (PBMC) and synovial fluid (SF)
samples from JIA patients and PBMCs from healthy controls (HC)
were analyzed by multicolor flow cytometry. Results are expressed as
the percentage of CD25CD69 T cells in the CD4 and CD8 T
cell compartments (n  23 per group). B, Cord blood (CB) mono-
nuclear cells, PBMCs from JIA patients, and PBMCs from healthy
controls were analyzed by flow cytometry and fluorescence in situ
hybridization. Results are expressed as the mean equivalent soluble
fluorescence (MESF) units of telomere fluorescence in
CD45RACD4 T cells (n  13 per group). C, T cells derived from
PBMC (PT) and SF (ST) samples obtained from JIA patients as well
as PBMC samples obtained from healthy controls were examined by
population-doubling assay, according to the method of Koetz et al
(22). Results are expressed as the number of doublings at 7-day
intervals (n  5 per group), and a fitted curve based on the complete
data set of cell counts was constructed. Data are shown as box plots.
Each box represents the 25th to 75th percentiles. Lines inside the
boxes represent the median. Lines outside the boxes represent the 10th
and 90th percentiles. P values were determined by Kruskal-Wallis
analysis of variance (ANOVA) (A and B) or by curve estimation
ANOVA (C).
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coexpressed histone H2AX, a senescence antigen
known to accompany telomere shortening (16).
As a system control, we also analyzed T cell
populations in our previously established in vitro senes-
cence system (21) to track phenotype changes in purified
CD28 T cells from healthy controls (Figure 2C). The
parental CD28 T cell culture had negative staining for
histone H2AX but had constitutive staining for CD31
on CD4 T cells and negligible staining for CD31 on
CD8 T cells. After 3 rounds of repeated stimulation,
many CD4 T cells in culture retained CD28 but lost
CD31. In contrast, most CD8 T cells lost CD28 but
gained CD31. Histone H2AX was negligible in cul-
tured CD4 T cells but was expressed by 30% of
cultured CD8 T cells (Figure 2C).
Collectively, these data showing a loss of CD28
expression, limitation of mitotic activity, and a gain of
CD31/histone H2AX expression among CD8 T cells
are consistent with cellular senescence.
Preponderance of CD31CD28nullCD8 T cells
with features of senescence in JIA. PBMCs and SF
samples from JIA patients and PBMCs from healthy
controls were examined to determine whether similar
T cells were found in vivo. Corroborating the report by
Wedderburn et al (5), we found an abundance of
CD28nullCD8 T cells in blood samples from JIA
patients as compared to healthy controls, with even
higher proportions in the patients’ SF samples (Figure
3A). Considering age-dependent loss of CD28 (6), the
data were normalized for age and showed higher annual
increases in CD28nullCD8 T cells in both blood and SF
from patients with oligoarticular JIA patients than in
those with polyarticular JIA. Inclusion of CD31 expres-
sion in the cell population analysis also showed higher
annual increases in CD31CD28nullCD8 T cells in
patients with oligoarticular JIA (Figure 3B).
Inspection of the cell frequency distributions
showed trends toward higher levels of CD31CD28null
Figure 3. CD31CD28nullCD8 T cells with features of senescence are overrepresented in patients with juvenile idiopathic arthritis (JIA).
Peripheral blood mononuclear cell (PBMC) and synovial fluid (SF) samples from JIA patients with oligoarticular (oligo) or polyarticular (poly)
disease and PBMC samples from healthy controls (HC) were analyzed for T cell phenotypes by multicolor flow cytometry. CD28null T cells (A) and
CD31CD28null T cells (B) are expressed as a percentage of the CD8 T cell compartment (n  15–51 samples per group), both the raw frequency
(left) and the age-adjusted frequency (right). Data are shown as box plots. Each box represents the 25th to 75th percentiles. Lines inside the boxes
represent the median. Lines outside the boxes represent the 10th and 90th percentiles. P values shown in A and B were determined by Kruskal-Wallis
analysis of variance.  P 0.05 versus healthy controls;  P 0.05 versus healthy controls and polyarticular JIA patients, by Tukey’s test. C–E,
Frequency distribution patterns of CD31CD28nullCD8 T cells (C) (same data set as in B), cell frequency data from 8 patients with paired PBMC
and SF samples (D), and cytograms of gated CD8 T cells from representative patients (patients 1–4) coexpressing the senescence antigens histone
H2AX and p16 (E).
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CD8 T cells in all patients as compared to the healthy
controls (Figure 3C). In 8 patients for whom paired
blood and SF samples were available (6 with oligoarticu-
lar JIA and 2 with polyarticular JIA) (Figure 3D), the
lowest frequency of CD31CD28nullCD8 T cells cor-
responded to the high-end frequency for healthy con-
trols. In addition, fresh CD8 T cells from the JIA
patients showed varying levels of histone H2AX, with
cases of coexpression of p16 (Figure 3E). In the CD4
T compartment however, CD28null cells, with or without
CD31 expression, were found sporadically, and their
frequency was not significantly different between
healthy controls and the 2 JIA groups (see Supplemen-
tary Figure 1, available on the Arthritis & Rheumatism
web site at http://onlinelibrary.wiley.com/doi/10.1002/art.
38015/abstract).
The prevalence of CD31CD28nullCD8 T cells
was unrelated to disease duration in either the oligoar-
ticular or the polyarticular JIA group. There was, how-
ever, an increasing, but not significant, trend toward
association with disease duration when the patients were
pooled (Figure 4A). Neither the age at disease onset
(Figure 4B) nor the medications taken (Figure 4C) was
related to the abundance of these cells regardless of
whether the patients were examined separately as 2
subgroups or together as 1 group.
CD31-driven TCR-independent activation of
CD8 T cells. Bioassays of primary CD31CD28null
CD8 T cells from JIA patients showed that ligation of
CD31 was sufficient to elicit protein phosphorylation
within 5 minutes and at levels equivalent to those seen
with ligation of the CD3–TCR complex (Figure 5A).
CD31 ligation with antibody or with recombinant CD38,
a known CD31 ligand (25), resulted in the induction of
CD25 and CD69 (Figure 5B) as early as 30 minutes and
the induction of granzyme and its cytolytic vesicle part-
ner CD107a (Figure 5C) within 6 hours. CD31 ligation
also induced high levels of interferon- and IL-10 in
culture supernatants at concentrations comparable to
those elicited by TCR/CD3 ligation (Figure 5D). TCR/
CD3 ligation, but not CD31 ligation, led to TNF
production, indicating differential outcomes of CD31
and TCR/CD3 triggering. These results were recapitu-
lated in an internal experimental system control using
JRT3 and Jurkat cells (Figure 5E), 2 classic models of T
cell activation (26). JRT3, a TCR/CD3-deficient somatic
variant Jurkat cell, displayed only a CD31-driven re-
sponse. Clearly, CD31 is a transducer of a cell-activating
signal in a TCR/CD3-independent manner.
DISCUSSION
The present study shows unequivocally that the
loss of CD28 expression on CD8 T cells is a property
of JIA, corroborating the original Wedderburn report
(5). Given that CD28 is normally sensitive to down-
modulation during conventional TCR-driven cell activa-
tion (27), accumulation of CD28nullCD8 T cells among
JIA patients is predictable due to the prevailing
immune-activated state in this disease. This is consistent
with our previous findings about the derivation of
CD28null cells in vitro from precursor CD28 cells
cultured in TNF, an effector cytokine in JIA (3), or
those repeatedly stimulated in senescence culture sys-
tems (20,21). In vivo, loss of CD28 occurs progressively
with age (6,15) and is thought to be a consequence of
infection with common and/or persistent pathogens (28).
Here, we report that the overabundance of
CD28nullCD8 T cells in JIA is significantly dispropor-
Figure 4. Frequency of CD31CD28null CD8 T cells in patients
with juvenile idiopathic arthritis (JIA) is unrelated to disease duration,
age at disease onset, or medication. Cell frequency data in patients
with oligoarticular (O) and polyarticular (P) JIA from Figure 3B (n 
15–51 samples per group) were plotted against A, the disease duration,
B, the age at disease onset, and C, the medications taken. As depicted
in A, there was a trend toward increasing CD31CD28null
CD8 T cell frequencies in peripheral blood mononuclear cell
(PBMC), but not synovial fluid (SF), samples with increasing duration
of disease, but this was not significant. Data are shown as box plots.
Each box represents the 25th to 75th percentiles. Lines inside the
boxes represent the median. Lines outside the boxes represent the 10th
and 90th percentiles.
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tionate with age. While we did not test for infection in
our cohort since there was no medical indication for it,
prevalence of these unusual cells is unlikely to be
associated with infection with persistent pathogens, such
as cytomegalovirus (CMV) that has been reported to
cause perturbations in the T cell repertoire in adults
(28). Repertoire studies in children with JIA and their
healthy counterparts have shown no significant differ-
ences in the levels of CD28 expression or in the overall
size of clonal populations, with or without exposure to
CMV (29). CMV surveillance in the US also indicates
that most Americans are exposed to the virus during
very early childhood, with up to 80% already CMV
seropositive by the age of 6 years (30). Thus, we suggest
that the prevalence of CD28nullCD8 T cells among
children with JIA is truly characteristic of the disease
state and is reminiscent of the age-disproportionate
prevalence of CD28nullCD4 T cells in young adults
with RA (7). We also found a very low frequency of
CD28nullCD4 T cells in JIA, which is consistent with a
previous report (31). This differential representation of
CD28null T cells in the CD8 and CD4 compartments in
JIA and RA, respectively, is consistent with the consen-
sus clinical opinion that JIA and RA are separate
diseases (1).
We have reported that the loss of CD28 expres-
sion on T cells is generally irreversible due to transcrip-
tional inactivation (11). CD28 loss is often associated
with gains in expression of novel receptors, as we have
shown in culture systems, in healthy adults of various
ages as well as in adults with RA (15,21,32). Here, we
show an unusually high level of expression of CD31 on
CD28nullCD8 T cells in patients with JIA, and the
frequency of this cell subset was, again, highly dispro-
portionate with age.
CD31 is a molecule present on granulocytes that
facilitates their normal transmigration to sites of injury/
inflammation (24). Kimmig and colleagues (33) also
reported that CD31 is coexpressed with TCR excision
circles (TRECs) in naive CD4 T cells. CD31 then
becomes down-regulated following activation of such
naive CD4 T cells and is irreversibly lost upon their
subsequent conversion to memory cells. The present
work confirms this observation. Our data show abundant
constitutive expression of CD31 on fresh blood CD4 T
cells, with a loss after repeated stimulation of the CD4
T cells. In contrast to the Kimmig report, however, our
data show that CD31 is expressed sporadically and at
low levels on blood CD8 T cells but is gained at high
levels by these CD8 T cells after repeated activation.
Figure 5. Ligation of CD31, independently of the T cell receptor (TCR), is sufficient to activate T cells. Peripheral blood mononuclear cell (PBMC)
and synovial fluid (SF) samples from JIA patients that had been enriched in CD31CD28nullCD8 T cells were incubated in anti-CD3 (T3),
anti-CD31 (31), IgG (Ig), medium (M), recombinant CD38-Ig (r38), or anti–T cell receptor / (anti-TCR [TR]). Shown are the induction of A,
protein tyrosine phosphorylation (pTyr) within 5 minutes (hydrogen peroxide [Per] positive control), B, CD25 and CD69 expression within 30
minutes, C, granzyme and CD107a expression within 6 hours, and D, interferon- (IFN), interleukin-10 (IL-10), and tumor necrosis factor 
(TNF) production in culture supernatants after overnight incubation. Similar CD31-driven, TCR-independent activation was noted in E, JRT3 and
Jurkat cells, which expressed constitutively high levels of CD31, as compared with controls. Results are representative of 5–10 independent
experiments.
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Although TREC was not measured in this study, both
our in vitro and in vivo data clearly show that CD31
expression on CD8 T cells was predominantly among
the CD28null T cells. Since CD28null T cells have a
memory/activated phenotype (20), CD31 expression on
CD8 T cells in JIA may be attributed to a post-thymic
activation event, which is in stark contrast to its consti-
tutive expression on naive CD4 T cells.
The age-disproportionate prevalence of
CD31CD28nullCD8 T cells in both SF and blood
from JIA patients indicates a role of these cells in
disease pathophysiology. Our data clearly show higher
annualized increases of CD31CD28nullCD8 T cells
in patients with oligoarticular JIA as compared to those
with polyarticular JIA. This observation corresponds to
the overall higher annualized frequency increase of
CD28null cells, regardless of CD31 expression, in oligo-
articular JIA as well. These are unexpected findings,
since oligoarticular JIA is generally considered a less
severe disease subtype than polyarticular JIA (1). The
prevalence of CD31CD28nullCD8 T cells was not
significantly associated with disease duration, age at
disease onset, or medications. A longitudinal analysis of
a larger cohort of patients is needed to determine
whether or not an abundance of CD31CD28nullCD8
T cells reflects overall stability of oligoarticular JIA or
perhaps an outcome trajectory toward either a “persis-
tent” or “extended” disease course of oligoarticular JIA
(1), or if perhaps they are bioindicators of disease
activity, irrespective of JIA subtype.
Whether the prevalence of CD31CD28null
CD8 T cells is specific to childhood arthritis or is a
general manifestation of a noninfectious chronic inflam-
matory state needs to be examined. Large populations of
CD28nullCD8 T cells have been found in some inflam-
matory conditions, such as ankylosing spondylitis (34),
but not in others, such as psoriasis, except when there is
concurrent CMV disease (29,35). Whereas the relevance
of CD31 in these diseases has yet to be examined, an
inflammatory state might not fully explain the emer-
gence of these cells in vivo.
CD31CD28nullCD8 T cells represent lympho-
cytes in advanced stages of senescence. Whether they
are derived in vitro or are naturally occurring in vivo, our
data show that these cells express high levels of 2 cell
senescence and mitotic inhibitory molecules, histone
H2AX and p16 (16,17). They also have limited or no
mitotic activity, even under highly stimulatory condi-
tions with allogeneic cells and anti-CD3 ligation. This
lack of mitotic activity may not be attributed to anergy,
since IL-2, a cytokine required for T cell proliferation
and a protector from anergy (36), is a component of the
stimulating milieu. Indeed, the culture microenviron-
ment is one that favors activation, as indicated by the
expression of CD69 on otherwise nondividing cells, since
senescence is not quiescence (17).
It might be noted that Prelog et al (37) have
argued that JIA has a “premature aging” phenotype,
based on their single observation that T cells from
patients have shorter telomeres than do those from
healthy children. Controversy remains as to whether
telomere shortening alone constitutes immune aging
(38). Aging of the organism is also not synonymous with
cell senescence (39). Nevertheless, our study reproduced
the observation about telomere shortening reported by
Prelog, but our study goes beyond this phenotype. Here,
we provide evidence for the overall restriction of the
proliferative capacity of the entire T cell compartment in
JIA, as well as the expression of senescence antigens and
the lack of mitotic activity of CD31CD28nullCD8 T
cells. To our knowledge, these data constitute the first
evidence of premature cellular senescence in JIA.
Despite their feature of senescence, CD31
CD28nullCD8 T cells are functionally active. CD31
serves as a TCR-independent immune receptor, in con-
trast to the classic costimulatory role of the defunct
CD28. CD31 triggering alone sufficiently elicits the
effector function of CD31CD28nullCD8 T cells, with
equivalent magnitudes of cellular responses achieved by
antibody ligation and by CD38, a natural ligand of CD31
(25). CD31 triggering alone induces the expression of
granzyme, consistent with the original reports about T
cell cytotoxicity as a pathogenic mechanism of JIA (40).
Our data also show that CD31 triggering is a
potent inducer of IL-10, but not TNF, which is more
effectively elicited by TCR triggering. Whether such
CD31-driven IL-10 production indicates regulatory ac-
tivity of CD31CD28nullCD8 T cells similar to that
ascribed to naturally occurring and inducible regulatory
CD4 T cells (41) needs to be examined further. It may
be noted, however, that CD28nullCD8 T cells have
been reported to have a regulatory/suppressive activity
in transplant settings in adults (42). It is not clear what
the relevant subset is, but an inhibitory subset of
CD28nullCD8 T cells expressing CD56, rather than
CD31, has been reported in a xenograft model of
rheumatoid synovium derived from adults with RA (43).
Although the relevance of such an inhibitory subset in
vivo has yet to be examined, the latter report is consis-
tent with emerging observations about differences in
regulatory activity between CD4 and CD8 T cells,
with IL-10–producing CD4 T cells being a distinct
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regulatory subset (41). However, CD4 T cell–derived
IL-10 also has well-documented immune stimulatory
effects in addition to its regulatory/inhibitory effect
especially in humans (41,44). Better understanding
about the context in which T cell–derived IL-10 pro-
motes or inhibits immune responses is needed.
While the biologic and/or clinical relevance of
CD8 T cell–derived IL-10 in JIA will have to be
examined further, systemic IL-10 has been implicated in
disease pathophysiology (45). There is also correlative
evidence that improvement of clinical symptoms with
steroid therapy is associated with lower plasma IL-10
levels (46). Of interest, therefore, is the source of
systemic IL-10 and whether the preponderance of
CD31CD28nullCD8 T cells might be linked to IL-10–
regulated pathways of JIA. This is especially true for
oligoarticular JIA, where certain IL-10 gene polymor-
phisms have been reported to distinguish between “per-
sistent” and “extended” courses of oligoarticular disease
(47). An important clinical consideration is whether or
not CD31-driven IL-10 production reflects regulatory
activity of CD31CD28nullCD8 T cells that influence
the outcome of JIA.
In summary, we report here our finding of a
preponderance of CD8 T cells that lack CD28 and
express CD31 in children with JIA. Our data show that
CD31CD28nullCD8 T cells represent a cell subset in
the advanced stages of senescence. This provides the
first evidence of premature T cell senescence in children,
which is consistent with our original thesis concerning
the role of cell senescence in immune-mediated diseases
(48). TCR-independent activation of these JIA T cells,
akin to the situation in adult-onset autoimmune and
chronic infectious diseases (49,50), is a form of immune
dysregulation. Further elucidation of CD31-driven im-
mune pathways and their influence on disease manifes-
tations will provide insights into the improvement of
therapy for JIA.
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